Business
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
LEXINGTON, Mass., March 25, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus’ neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster
About this update from Agenus Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"First oral presentation of BOT/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors","length":107,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"New data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT/BAL Phase 1 trial to be presented","length":121,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":228,"olType":false},{"type":"text","content":"LEXINGTON, Mass., March 25, 2025--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus’ neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster featuring new data from the advanced hepatocellular carcinoma (HCC) cohort of a Phase 1 study evaluating BOT/BAL in patients with advanced solid tumors. Data from two separate, independent studies of neoadjuvant treatment with BOT/BAL in colorectal cancer--UNICORN and NEST-- were presented earlier this year at ASCO-GI.","length":837,"tagName":"p"},{"type":"text","content":"Oral Presentation Details:","length":26,"tagName":"p"},{"type":"text","content":"Presentation Title: Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: First results of the pan-cancer NEOASIS study (NCT06279130)Presenting Author: Myriam Chalabi, MD, Netherlands Cancer InstituteSession Title: Aiming for Cure: Adjuvant and Neoadjuvant ApproachesSession Date and Time: 4/28/2025; 2:30:00 - 4:30:00 PM CTAbstract Presentation Number: CT130","length":404,"tagName":"p"},{"type":"text","content":"Poster Presentation Details:","length":28,"tagName":"p"},{"type":"text","content":"Presentation Title: Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma (NCT03860272)Presenting Author: Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer CenterSession Title: Late-Breaking Research: Clinical Research 3Session Date and Time: 4/29/2025; 2:00 - 5:00 PM CTLocation: Poster Section 53Poster Board Number: ...